In phase 2 study of INO-5401 in combination with cemiplimab, Inovio Pharmaceuticals Inc (NASDAQ:INO) achieved success in ensuring the progression-free survival of patients who are diagnosed with GBM (glioblastoma multiforme). The phase 2 study is conducted using INO 9012, and INO 5401 in combination with a PD-1 blocking antibody – Libtayo on fifty-two patients diagnosed […]
Sign Up To Get Our Instant Alerts!
- Japanese Premier Declares COVID-19 State of Emergency in Tokyo 139 views
- Toyota Suspends Production at 2 Plants in Japan Citing Chip Shortage 81 views
- InnerScope Hearing Technologies (OTC: INND) Launches Its iHEAR Brand of OTC Hearing Aids on CVS.com 77 views
- China Unveils Maglev Train With a Top Speed of 600 kph 77 views
- Google Gives Spotify its Own In-App Payment Option as Part of a New Pilot 73 views